New hope for scleroderma: experimental drug CM-101 enters Mid-Stage trial
NCT ID NCT06210945
First seen May 02, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This study tests an experimental drug called CM-101 in people with systemic sclerosis (scleroderma), a rare disease that causes hardening and tightening of the skin and can damage internal organs. About 45 adults will receive either the drug or a placebo to check if it is safe and tolerable. The goal is to see if CM-101 can reduce inflammation and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.